GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (FRA:D8Y0) » Definitions » Short Percentage of Float

Sandoz Group AG (FRA:D8Y0) Short Percentage of Float


View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Sandoz Group AG's Short Percentage of Float

For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sandoz Group AG's Short Percentage of Float Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Sandoz Group AG's Short Percentage of Float falls into.


Sandoz Group AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (FRA:D8Y0) » Definitions » Short Percentage of Float
Comparable Companies
XSWX:SFZN XSWX:PPGN ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 HKSE:03692 NBIX NSE:DIVISLAB BOM:500124 VTRS SZSE:000963 XPAR:IPN SHSE:600085 XTAE:TEVA SHSE:600196
Traded in Other Exchanges
SDZXF:USA SDZNY:USA SDZz:UK 0SAN:UK D8Y0:Germany SDZ:Switzerland
Address
Forum 1, Novartis Campus, Basel, CHE, CH-4056
Website
https://www.sandoz.com
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as the first US biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in its pipeline.

Sandoz Group AG Headlines

No Headlines